Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultibro Breezhaler versus ipratropium + salbutamol nebulization in stable COPD
NL-OMON42656Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of indacaterol + glycopyrronium, ipratropium bromide and salbutamol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: FEV1 AUC from 0 to 6 hours. Started Dec 2015; status: active, not recruiting.
02
Drugs
indacaterol + glycopyrroniumipratropium bromidesalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON42656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42656.